uniQure price target lowered to $25 from $31 at Barclays

Barclays analyst Eliana Merle lowered the firm’s price target on uniQure (QURE) to $25 from $31 and keeps an Equal Weight rating on the shares. While Vinay Prasad’s departure from the FDA could be a positive, regulatory uncertainty continues for uniQure, the analyst tells investors in a research note. Barclays thinks a Phase 3 trial in Huntington’s disease will likely be required for uniQure.